|
Title
|
Published
|
Price
|
|
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
By: BioSeeker Group AB
This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of
|
more...
|
10/29/2009
|
$3,500.00
|
|
Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning
By: BioSeeker Group AB
This report includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different
|
more...
|
8/25/2009
|
$3,500.00
|
|
Lymphoma Drug Development Strategies at Work - Define Your Competition
By: BioSeeker Group AB
This report includes defined and up to date development strategies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications
|
more...
|
6/22/2009
|
$2,750.00
|
|
Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
By: BioSeeker Group AB
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an
alternative to small molecule drugs. Alternative binding peptide molecules, derived from
combinatorial scaffold libraries, are now challenging traditional antibodies. This
|
more...
|
5/28/2009
|
$3,400.00
|
|
Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
By: BioSeeker Group AB
This report includes defined and up to date development strategies for 175 leukemia drugs (>250
projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are
further dived into the sub-indications of
|
more...
|
4/3/2009
|
$3,100.00
|
|
Brain Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases in the developed world. While
|
more...
|
2/20/2009
|
$2,099.00
|
|
Immunotherapy in Oncology: Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the fields of antibodies, vaccines, and immunostimulators
|
more...
|
1/20/2009
|
$2,799.00
|
|
Apoptosis in Oncology: Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells.
There are
|
more...
|
1/20/2009
|
$2,099.00
|
|
Prostate Cancer: Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the
|
more...
|
1/20/2009
|
$2,099.00
|
|
Analytical Tool - Hematological Cancers
By: BioSeeker Group AB
Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is at the same time a
|
more...
|
1/20/2009
|
$8,330.00
|
|
Antibodies in Oncology: Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in
|
more...
|
1/20/2009
|
$2,099.00
|
|
Analytical Tool - The Commercial Success of Cancer Therapeutic Antibodies
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Cancer Therapeutic Antibodies" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer. It is
|
more...
|
1/20/2009
|
$5,740.00
|
|
Breast Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
There are today at least 250 anti-angiogenic/vascular disruptive/vascular targeting agents drugs in active development for the treatment of various cancers, from early preclinical to marketed drugs. In addition, the accumulated number of
|
more...
|
1/20/2009
|
$2,099.00
|
|
Analytical Tool - Colorectal Cancer
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Colorectal Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal cancer R&D and business development. It is at the same time
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Melanoma
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Melanoma" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in melanoma R&D and business development. It is at the same time a
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Vaccines
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Cancer Vaccines" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer vaccine drug development. It is at the same time a
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Angiogenesis in Oncology
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Angiogenesis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in anti-angiogenic drug development for the treatment of cancer. It is
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Competitive Outlook on Apoptosis in Oncology
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Apoptosis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in apoptopic drug development for the treatment of cancer. It is
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Prostate Cancer
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Prostate Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer R&D and business development. It is at the same
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Breast Cancer
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Breast Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in breast cancer R&D and business development. It is at the same
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Protein Kinase Inhibitors in Oncology
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Protein Kinase Inhibitors in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase inhibitors (PKIs)
|
more...
|
1/20/2009
|
$4,340.00
|
|
Liver Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
There are today at least 107 therapeutics targeting liver cancer in active development, from early preclinical to marketed drugs. In addition, the accumulated number of ceased drugs over the last three years
|
more...
|
1/20/2009
|
$1,399.00
|
|
Pancreatic Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
There are today at least 190 therapeutics targeting pancreatic cancer in active development, from early preclinical to marketed drugs. In addition, the accumulated number of ceased drugs over the last three years
|
more...
|
1/20/2009
|
$2,099.00
|
|
Ovarian Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication
|
more...
|
1/20/2009
|
$2,099.00
|
|
Renal Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being
|
more...
|
1/20/2009
|
$2,099.00
|
|
Title
|
Published
|
Price
|
(0 items)
